New!
Portfolio
Login
/
Sign Up
Search
Industries
Technology
Energy
Media
Finance
Green Issues
China
All Concepts
Metals
Energy
Meats
Grains
Softs
ETFs
Indices
Currencies
Geographies
Exchanges
Rates
How To Invest
Personal Finance
Options 101
Definitions
close
close
close
close
Send us Feedback
EResearch Technology (ERES)
SUMMARY
BULLS
BEARS
TOPICS
DATA CENTRAL
STOCK CHART
OPERATING METRICS
REVENUE SOURCES
SEC FILINGS
BALANCE
INCOME
CASH FLOW
Topic Listing for EResearch Technology
Accounting Stock-based Compensation
Acquire Make Investments Companies Technologies Cause Disruption Business
Action Governance Nominating Committee
Action Nominating Committee
Administration
Advertising Costs
Agreements Management
Amendment Termination
Annual Meeting
Attend Annual Meeting
Audit Committee
Audit Committee Oversight
Audit Committee Report Audited Consolidated Financial Statements
Available Http Proxydocscom Eres
Available Information
Background
Basis Presentation
Beneficial Ownership Reporting Compliance
Board Directors Committees
Board Directors Meetings Committees
Board Directors Recommends Stockholders Vote Election Mckelvey Scheppmann
Board Directors Recommends Stockholders Vote Election Morganroth Phillips
Bonus Plan
Bruce Johnson
Business Combinations
Business Combinations Valuation Intangible Assets
Business Seriously Harmed Dependence Limited Number Suppliers
Candidates Election
Capacity Constraint System Failures Result Loss Liability Clients
Cardiac Safety Equipment Own Lease Become Obsolete Due
Cardiac Safety Market Clinical Trials
Cash Equivalents
Cautionary Statement Forward-looking Information
Ceo Employment Agreement
Certain Relationships Related Party Transactions
Change Vote After Return Proxy Card
Changes Internal Control Over Financial Reporting
Clients
Clients Derive Substantial Revenue Therefore Loss Even Few
Clinical Trial Sponsors Cros Not Shift Existing Paper-based
Code Ethics Business Conduct
Compensation Committee
Compensation Committee Interlocks Insider Participation
Compensation Committee Report
Compensation Directors
Compensation Individual Named Executive Officers
Compensation Named Executive Officers
Compensation Philosophy
Competition
Comprehensive Income
Concentration Credit Risk Significant Clients
Conclusions Regarding Disclosure Controls Procedures
Consent Independent Registered Public Accounting Firm
Consolidated Balance Sheet Data
Consolidation Among Clients Cause Lose Decrease Market Products
Contents
Contingencies
Continuing Named Executive Officers
Controls Procedures
Costs Revenues
Costs Solicitation
Course Conducting Business Possess Deemed Personal Medical Information
Critical Accounting Policies
Departure Directors Principal Officers Election Appointment
Depend Entirely Clinical Trial Market Downturn Cause Revenues
Depreciation Amortization Long-lived Assets
Director Compensation
Director Independence
Director Nominations
Documents Incorporated Reference
Ede
Elements Compensation
Eligibility
Eligible Participants
Employees
Entitled Vote Annual Meeting
Entry Material Definitive Agreement
Erc
Eresearchtechnology Announces Appointment New Chief Financial Officer
Eresearchtechnology Inc
Eresearchtechnology Inc Announces Pending Retirement Chief Executive Officer
Eresearchtechnology Inc South 17th Street Philadelphia 19103
Eresearchtechnology Inc Subsidiaries
Eresearchtechnology Inc Subsidiaries Consolidated Statements Operations Except Per
Eresearchtechnology Inc Subsidiaries Valuation Qualifying Accounts
Eresearchtechnology Inc Updates Outlook Sets Earnings Conference Call
Eresearchtechnology Reports Results
Eresnet
Estimates
Event Unable Satisfy Regulatory Requirements Relating Internal Control
Executive Compensation
Executive Overview
Exhibits
Existing Equity Compensation Plans
Expert
Extensive Governmental Regulation Clinical Trial Process Require Costly
Failure Continue Expand Business Manage Growth Successfully Disrupt
Failure Establish Maintain Partnerships Other Strategic Alliances Delay
Failure Establish Maintain Strategic Alliances Delay Development Products
Failure Expand Business Manage Growth Successfully Disrupt Operations
Fair Market Value
Fair Value Disclosures Prior Sfas 123r Adoption
Fda Recommend Different Approach Measure Drug Effects Interval
Federal Income Tax Consequences
Financial Statements Exhibits
Foreign Currency Risk
Form 10-k
Form 10-q
Form 8-k
Future Operating Results Uncertain Fluctuate Fail Meet Expectations
General
General Economic Conditions Fail Improve Continue Deteriorate Operations
General Economic Conditions Worsen Potential Clients Unwilling Make
Goodwill
Goodwill Subject Impairment Result Significant Expense
Governance Nominating Committee
Government Regulation
Grants Plan Based Awards
Held 2008
Income Taxes
Incur Liability Result Providing Cardiac Safety Analysis Interpretation
Incur Liability Result Providing Consulting Cardiac Safety Analysis
Indemnification
Index
Index Consolidated Financial Statements Statement Schedule
Inflation
Intellectual Property
Interest Rate Risk
International Operations Expose Additional Risks
Interruptions Delays Service Third-party Providers Impair Delivery Hosted
Introduction
Issuer Purchases Equity Securities
Joseph Esposito
Leases
Long-lived Assets
Long-term Performance Awards
Managements Annual Report Internal Control Over Financial Reporting
Managements Report Financial Statements
Managements Report Internal Control Over Financial Reporting
Maximum Fair Market Value Incentive Stock Options
Net Income Per Common Share
New Plan Benefits
Nominating Procedures
Non-transferability Stock Option
Not Able Effectively Integrate Recent Transactions Historic Operations
Not Successful Competing Against Others Providing Similar Product
Not Successful Competing Against Others Providing Similar Products
Notice Annual Meeting Stockholders Held 2007
Operating Expenses
Operating Segments Geographic Information
Operations
Option Exercises
Option Price
Options
Other Commitments Contingencies
Other Income Net
Other Matters
Overview
Part
Part Other Information
Parties Claim Infringe Intellectual Property Rights Result Loss
Parties Claims Damages Against Continue Result Unfavorable Settlement
Partnerships
Pay Costs Soliciting Proxies Behalf Board Directors
Payment Manner Exercise
Performance Shares
Period Stock Option
Philadelphia
Potential Liability Insurance
Principles Consolidation
Product Initiatives
Project Assurance Implementation
Property Equipment
Proposal
Proxy Statement
Purpose
Qualified Performance-based Compensation
Quantitative Qualitative Disclosures Market Risk
Quarterly Period 2006
Rapidly Changing Technology Impair Ability Develop Market Solutions
Ratification Independent Registered Public Accountants
Ratification Independent Registered Public Accountants Proposal
Recent Accounting Pronouncements
Recent Developments
Recent Pronouncements
Recent Transactions
Reclassifications
Registrants Telephone Number Including Area Code Securities Registered
Related Party Transactions
Report Independent Registered Public Accounting Firm
Report Independent Registered Public Accounting Firm Internal Control
Reports Revenue 176 Earnings Per Share 004
Reports Revenue 214 Earnings Per Share 004 Including
Reports Revenue 254 Earnings Per Share 010
Repricing Without Stockholder Approval
Research Development
Restricted Stock
Restricted Stock Long-term Performance Awards Shares
Results Operations Financial Condition
Revenue Recognition
Revenues
Review External Data
Richard Baron Assume Duties
Rights After Termination Employment
Risk Factors
Role Compensation Committee
Role Compensation Committee Chief Executive Officer
Sales Large Blocks Common Stock Cause Market Price
Sales Marketing
Securities Exchange Act 1934
Several Large Clients Derive Substantial Revenue Therefore Loss
Short-term Investments
Short-term Long-term Investments
Signatures
Software Development Costs
Software Products Complex Contain Undetected Errors Lead Increase
Special Executive Officers Registrant
Stock Appreciation Rights
Stock Option Plans
Stock Split
Stock Splits
Stock-based Compensation
Stockholder Communications Board Directors
Stockholder Proposals
Stockholder Return Performance Graph
Stockholders Entitled Vote
Submission Matters Vote Security Holders
Supplemental Cash Flow Information
Tax Consequences
Tax Considerations
Tax Effect Related Share-based Compensation Expense
Tax Effect Related Stock-based Compensation Expense
Technology
Termination Material Definitive Agreement
Time Exercise Option
Translation Foreign Financial Statements
Unable Protect Proprietary Technology Maintain Technological Advantages Lose
United States Securities Exchange Washington 20549
United States Securities Exchange Washington 20549 Form 8-k
Unregistered Sales Equity Securities Proceeds
Valuation Assumptions Options Granted
Valuation Assumptions Options Granted 2006
Valuation Assumptions Options Granted 2006 2007
Vote Person
Vote Shares Held Street Name
Voting
Voting Proxies
Website
What Constitutes Quorum
What Fail Instruct Broker
What Now
What Purpose Annual Meeting
What Recommendations Board Directors
What Vote Required
What Voting Rights Stockholders
Bet you've never seen portfolio analytics like these.
Introducing
SigFig
— from the creators of
Take Tour